EU Panel Recommends Olaparib Tablets for Ovarian Cancer, Regardless of BRCA Status

February 23, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of olaparib tablets as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA status. A capsule formulation of olaparib is currently approved in the European Union for use in this … (leggi tutto)